Literature DB >> 18798105

Differences in germinal centre and non-germinal center phenotype in gastric and intestinal diffuse large B-cell lymphomas.

Kisha A Mitchell1, William G Finn, Scott R Owens.   

Abstract

The gastrointestinal tract is the most common extranodal site of lymphoma, and the most common gastrointestinal lymphoma is diffuse large B-cell type (DLBCL). DLBCL can be separated into germinal centre (GCP) and non-germinal centre phenotypes (non-GCP) using CD10, BCL-6 and MUM1 immunohistochemistry, but primary gastrointestinal DLBCL has not been extensively studied. We investigated 48 cases of primary gastrointestinal DLBCL (33% involving the small intestine, 50% the stomach, 13% the large intestine and 4% the ileocecal junction) and found that most (88%) DLBCL in the intestines were of GCP, while only 58% of gastric DLBCL were of GCP. This difference in GCP and non-GCP in gastric vs. intestinal DLBCL may be due to variations in lymphomagenesis reflecting acquired vs. native mucosa-associated lymphoid tissue. There was no significant difference in either overall survival or disease-free survival between the germinal centre and non-germinal centre groups. The distribution of Helicobacter pylori in different gastric DLBCL phenotypes raises interesting questions about the pathogenesis of H. pylori-associated lymphomas.

Entities:  

Mesh:

Year:  2008        PMID: 18798105     DOI: 10.1080/10428190802238552

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  2 in total

1.  Correlation between immunophenotype classification and clinicopathological features in chinese patients with primary gastric diffuse large B-cell lymphoma.

Authors:  Zhang Zizhen; Cao Hui; Shen Yanying; Shen Danping; Liu Jiahua; He Chao; Ni Xingzhi
Journal:  Pathol Oncol Res       Date:  2012-12-14       Impact factor: 3.201

2.  MYC expression in concert with BCL2 and BCL6 expression predicts outcome in Chinese patients with diffuse large B-cell lymphoma, not otherwise specified.

Authors:  Li-Xu Yan; Yan-Hui Liu; Dong-Lan Luo; Fen Zhang; Yu Cheng; Xin-Lan Luo; Jie Xu; Jie Cheng; Heng-Guo Zhuang
Journal:  PLoS One       Date:  2014-08-04       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.